Perfluorinated blood substitute - gas transport donor blood substitute: formulation and treatment

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a formulation of a perfluorinated blood substitute emulsion for biomedical applications, containing: perfluorinated hydrocarbons, emulsifying agents and an electrolyte solution differing by the fact that it contains a binary mixture of two perfluorinated hydrocarbons in ratio 1.55 to 1.99 in the concentration of 5 - 1000 g/l, with an average particle size of a perfluororganic compound of 25 - 250 nm; a binary mixture of the emulsifying agents in ratio 1.55 to 1.99 that are non-ionic block copolymers of ethylene oxide and propylene oxide - proxanoles: proxanole-268/proxanole-168; proxanole-268 in the concentration of 1 - 200 g/l with the molecular weight of 7 - 14 thousand Da; proxanole-168 in the concentration of 1 - 200 g/l with the molecular weight of 5 - 7 thousand Da; the electrolyte solution: NaH2PO4 - 0.18-0.25 g/l; NaCl - 5.5-6.5 g/l; and/or KCl - 0.37-0.41 g/l; and/or MgCl2 - 0.17-0.21 g/l; and/or NaHCO3 - 0.35-0.7 g/l; and/or glucose - 1.5-2.5 g/l.

EFFECT: invention ensures formulating the perfluorinated blood substitute with better aggregation and sedimentation stability and lower toxicity.

2 cl, 9 ex

 

The invention relates to biomedical and pharmaceutical industry and relates to a composition and means for treatment on the basis of performoperation-proksanola blood emulsions intended for use as synthetic perfluorocarbon blood substitute with gas transport function, as well as perfusion, contrast and cosmetics.

Prior art

The compositions of perfluorocarbon emulsions.

Perfluorocarbon the blood is emulsion-based performancesin compounds is a complex multiphase colloidal systems used in biomedical field as multifunctional medicines, in particular as a gas substitute blood for compensation of blood loss.

Colloidal-chemical determination of perfluorocarbon getparentdir emulsions are direct, concentrated, high - and freely-dispersed, heterogeneous, thermodynamically unstable lifornia colloidal systems with excess free surface energy and a huge area of gas exchange (sorption active surface phases), in which the dispersed phase is insoluble ultrafine chemically inert perfluorocarbon particles covered with the adsorption-solvate layer from the surface is chestno-active substances and saves some time at low temperatures, aggregate stability and uniform distribution of the dispersed phase volume of the dispersion structured environment.

High energy saturation of perfluorocarbon particles their ultradispersed creates unique properties of emulsion systems and puts them in a special transitional nanoscale region (10-8m), near colloidal (10-9m) and molecular (10-10m) the state of matter. This special state of perfluorocarbon dispersion of nanosystems is manifested in their high biological activity, reactivity and physical interaction with many substances and gases.

In compositions for biomedical purposes on the basis of perfluorocarbon emulsions are used, as a rule, several types performancesin compounds (PFOS). One of them is selected from the group (C8-C10containing, for example, perpendicular (PFD) C10F18or performapply (PPTP) C9F21N, or perforative (PFOB) C8F17Br, the second group (C11-C12containing, for example, performatilicious-piperidine (PFMRP) C12F23N or performability (PFTB) C12F27N. Data perfluorocarbons dissolve about 40 vol.% oxygen (pO2=760 mm Hg) and 150-190% vol. carbon dioxide (pCO2=760 mm Hg), as a result, they started to be used as the main component of casinosites, when creating synthetic cruisemax the participating funds. However, perfluorocarbons not soluble in water and other liquids, so you can use them only in the form of emulsions with a certain amount of perfluorocarbon particles covered with a layer of emulsifier (proxanol is chosen or phospholipid). The smaller the particle size of the emulsion, the better, because the emulsion is injected intravenously and large particle size, emulsion formulations can cause embolism (blockage) of the vessels, and severe adverse reactions to the presence of coarse particles of the emulsion. The connection of the first type quickly (within months) removed from the body, but do not provide sufficient stability of their emulsions, compounds of the second type, on the contrary, give emulsions of high stability, allowing you to store them without freezing, but they for several years not eliminated from the body.

Known composition of the emulsions containing, for example, perpendicular and performapply, emulsifying agents, for example, a copolymer of polyoxyethylene-propylene (pluronic F-68, domestic analogue - proxanol is chosen 268), phospholipids of egg yolk or soybean phospholipids and water (USSR author's certificate No. 797546, publ. in bull. "Discoveries, inventions...", 1981, No. 2). In accordance with this composition, the concentration of the perfluorocarbon is 24% in a physiologically acceptable aqueous medium. The disadvantages of this part of the decree is nom the invention should be considered, the composition of the emulsion has a fairly coarse size particles are not able to be sterilized and stored in unfrozen form.

In another 20% emulsion, prepared for medical purposes on the basis of the PFD and PPTP - Fluosol-DA 20%, the Japanese company, as an emulsifier was used proxanol is chosen and phospholipids of egg yolk. However, the average diameter of the particles in the composition of the emulsion was also large, due to the fact that at high temperatures in the process of emulsification and pasteurization is the integration of the particles of the emulsion. In addition, the particles used in the composition of the emulsions of perfluorocarbons quickly escalated even at room temperature (T. Mitsuno et al., "Intake and retension of perfluorochemical substance of Fluosol-DA in human res". Proceedings of the 5. Int. Sympos. On Oxygen Carring Colloidal Blood Substituts, Meinz, March, 1981, p.220). The composition of the emulsion is stored only in frozen form, as after 8-12 hours of storage at room temperature is the integration of the particles of the emulsion and, therefore, it becomes impossible its clinical application.

Closest to the claimed composition - composition-based emulsion performancesin compounds for biomedical purposes (patent RF №2162692, publ. in bull. "Discoveries, inventions..." 10.02.2002, No. 4), which has a two-component mixture consisting of: performanceline, performancebased, perfe is methylcyclohexylamine, performability, a concentration of from 1% to 20%emulsifiable the proxanol is chosen-268. Disadvantage and difference of this composition is used as emulsifier one synthetic stabilizer and the impossibility of rapid defrost and clinical use after storage for more than 2 weeks in unfrozen form at +4C°.

Closest to the claimed composition - composition-based emulsion performancesin compounds for biomedical purposes (patent RF №2367415, publ. in bull. "Discoveries, inventions..." 20.09.2009, No. 26, which comprises a two-component mixture consisting of: performancebased, performancecriteria, performability, a concentration of from 1% to 100%emulsifiable of proxanol is chosen-268. Disadvantage and difference of this composition is used as emulsifier one synthetic stabilizer and the impossibility of rapid defrost and clinical use after storage for more than 2 weeks in unfrozen form at +4C°.

Closest to the claimed composition - composition-based emulsion performancesin compounds for biomedical purposes (patent RF №2199311, publ. in bull. "Discoveries, inventions..." 27.02.2003, No. 6), which includes a two-component mixture consisting of: performanceline, performancebased, performancestick-hexylpyridine, perftoran is filamina, concentration from 1% to 30%, emulsifiable of proxanol is chosen-268. Disadvantage and difference of this composition is used as emulsifier one synthetic stabilizer and the impossibility of rapid defrost and clinical use after storage for more than 2 weeks in unfrozen form at +4C°.

Disclosure of the invention.

The first object of the present invention is to provide a highly stable blood composition on the basis of performoperation-proksanola emulsion distinguished: first, to increase the stability of the composition, uses a binary mixture of two perfluorocarbons in a certain ratio, in which the smaller part one perfluorocarbons (more stable) refers to the most other perfluorocarbons (less stable), as most of the entire amount, secondly, to reduce the toxicity of the composition, uses a binary mixture of two emulsifiers, in a certain ratio, in which the smaller part one emulsifier (less toxic) refers to the most other perfluorocarbons (more toxic), how large the entire value, which significantly improves the physico-chemical, medical and biological properties of the present composition.

The second objective of the invention is the application of the developed tools based on perftool the Ural-proksanola blood emulsions in various biomedical fields, including, as a gas substitute for blood.

First the problem is solved in that in the known structure on the basis of perfluorocarbon blood emulsion for biomedical purposes, including:

perfluorocarbons, emulsifying agents and an electrolyte solution, characterized in that it contains a binary mixture in a ratio of from of 1.55 to 1.99 of two perfluorocarbons:

- performanceline/performapply;

- performanceline/performability;

- performanceline/performancecriteria;

- performancebased/performapply;

- performancebased/performability;

- performancebased/performancecriteria;

- performapply/performancecriteria;

- performapply/performability;

- performancecriteria/performability;

- perfluorocarbons a concentration of 5 g/l to 1000 g/l, with an average particle size of PFOS from 25 to 250 nm;

binary mixture in a ratio of from of 1.55 to 1.99 of two emulsifiers-nonionic block copolymers of ethylene oxide and propylene oxide - proksanola:

- proxanol is chosen - 268/proxanol is chosen - 168;

- proxanol is chosen - 268 a concentration of 1 g/l to 200 g/l with a molecular weight of from 7 to 14 thousand Yes;

- proxanol is chosen - 168 a concentration of 1 g/l to 200 sec with a molecular mass of from 5 to 7 thousand Yes;

electrolyte solution: NaH2PO4- 0,18-0,25 g/l; NaCl - 5,5-6,5 g/l; and/or KCl - 0,37-0,41 g/l; and/or MgCl2- to 0.17-0.21 g/l; and/or NaHCO3- 0,35-0,70 g/l; and/or glucose - 1.5-2.5 g/L.

The second task is solved in that the tool - based composition of perfluorocarbon blood emulsions intended for use as a synthetic perfluorocarbon blood substitute and means for the treatment of various diseases, characterized in that the composition can be used as a gas substitute blood for intravenous, intra-arterial, oral, endocavitary applications, as well as perfusion, contrast and cosmetic products, before eating can divorce any compatible with the emulsion solution or composition, including antiviral, antibacterial, antifungal composition can also be used as an external tool for cosmetic and medicinal ointments or creams for the treatment of wounds, ulcers, and other external diseases.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers, is composed of d is two perfluorocarbons with different physico-chemical properties, changing from lipophilic to Express lipophobic properties and up to two emulsifiers with different physico-chemical properties and varying degrees of toxicity.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers, has a certain range of different physico-chemical and biomedical properties due to the lipophilic-lipophobic properties forming part of perfluorocarbons and emulsifiers that increases the efficiency and the quality of the emulsion; reduces intramolecular diffusion; increases aggregation and sedimentation stability of the emulsion particles; improves emulsification; reduces the toxicity of the emulsion; reduces the number of adverse reactions emulsion; extends the field of application. This factor gives an advantage over other formulations peers.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers has a proportion of from of 1.55 to 1.99 between the two perfluorocarbons selected empirically. When this proportional the AI perfluorocarbon concentration increases more stable perfluorocarbon, significantly (1.5 times) the aggregation and sedimentation stability of the entire dosage form presents the composition during long-term storage in unfrozen form at a temperature of+4°C compared with that of the peers. This factor is one of the key, giving an advantage over other formulations peers.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers with repeated thawing/freezing is preferable for the stability of the composition of the particles of the emulsion than analogues. Thus, compounds analogous to assume 5-and time defrost/frost compositions, due to the sharp escalation of the particles of the emulsion and not the possibility of further use. Presents the composition undergoes a 7-fold thawing/freezing with subsequent use. This factor is one of the key, giving an advantage over other formulations peers.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion stabilized with a two-component mixture of em is ligation can unfreeze actively in several minutes (5-10 minutes) at a temperature defrost from +50°to +80°C unlike compositions counterparts, which are unfrozen passively at room temperature for several hours. This factor is one of the key, in connection with the possible application of the developed composition in the provision of emergency assistance to patients in disaster medicine.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers has a proportion of from of 1.55 to 1.99 between the two emulsifiers: proxanol is chosen-268 and proxanol is chosen-168, chosen empirically. When this ratio decreases, the share of more toxic emulsifier - proxanol is chosen 268, which significantly reduces the toxicity of all dosage forms of the presented composition. This factor is one of the key, giving an advantage over other formulations peers.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers may be used as the polyfunctional synthetic perfluorocarbon drug, as gas substitute donor CROs and, or for the treatment of various diseases.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers can be used as synthetic perfusion funds.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers can be used as synthetic contrast media.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola emulsion, stable two-component mixture of emulsifiers can be used for external use as the basis of water-soluble medicinal ointments or creams for application, irrigation, wetting, long not healing wounds, ulcers, and other external diseases.

The proposed composition with improved aggregation and sedimentation stability and reduced toxicity on the basis of two-component performoperation-proksanola EMU is sii, stable two-component mixture of emulsifiers can be used for external use as the basis of cosmetic water-soluble ointments or creams for skin care.

Thus, all presented positive factors contributes to a more effective and safe use of the proposed performoperation-prakseologia gatoperezoso emulsion composition in medicine and biology, extend the field of its application.

Detailed description of the invention. The receiving part.

Example 1. The receiving structure 1% performoperation-proksanola emulsion PFD/PPTP.

Perfluorocarbon mixture PFD/PPTP (in a ratio of 1.55) in the amount of 0.5 ml, containing sample (liquid) 0,608 g PFD and 0,392 g PPTP, mixed with 99.5 ml of an aqueous solution containing 0.2 gram of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The specific density of perfluorocarbons ~2, so 1 gram of PFOS has a volume of 0.5 ml of the mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added a simplified version of electrolyte solution to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFD/PPTP in the ratio of 1.55; PF is - between 6.08 g/l; PPTP - to 3.92 g/l; emulsifiers - 2.0 g/l; NaCl - 6.0 g/l; NaH2PO40.2 g/l

Received performoperation-proksanola composition can be used as blood money for intravenous and intra-arterial injection, oral, intraoral, internal and external use.

Example 2. Receive 10% performoperation-proksanola emulsion PFD/PTBA.

Perfluorocarbon mixture PFD/PTBA (in proportion 1,63) in an amount of 5 ml containing sample (liquid) 6.2 g PFD and 3.8 g PFTB, was mixed with 95 ml of an aqueous solution containing 2 grams of a binary mixture of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added a simplified version of electrolyte solution to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFD/PFTB in proportion to 1.63; PFD - 62 g/l; PTBA - 38 g/l; emulsifiers - 20 g/l; NaCl - 6.0 g/l; NaH2PO40.2 g/l

Received performoperation-proksanola composition can be used as blood money for intravenous and intra-arterial injection, oral, intraoral, internal and external the application.

Example 3. Receive 20% performoperation-proksanola emulsion PFD/PFMRP.

Perfluorocarbon mixture PFD/PFMRP (in proportion 1,63) in an amount of 10 ml containing sample (liquid) 12.4 g PFD and 7.6 g PFMSP, was mixed with 90 ml of an aqueous solution containing 4 grams of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added to an electrolyte solution to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFD/PFMSP in proportion to 1.63; PFD - 124 g/l; PFMSP - 76 g/l; emulsifiers - 40 g/l; NaCl - 6.0 g/l; KCl - 0.39 g/l; MgCl2to 0.19 g/l; NaHCO3- 0.65 g/l; NaH2PO40.2 g/l; glucose - 2.0 g/L.

Received performoperation-proksanola composition can be used as a blood and perfusion means when intracavitary, internal and external use.

Example 4. Obtaining a composition of 60% performoperation-proksanola emulsion PFOB/PPTP.

Perfluorocarbon mixture PFOB/PPTP (in proportion 1,63) in an amount of 30 ml containing sample (liquid) 37,2 g PFOB and 22.8 g PPTP was mixed with 70 ml of an aqueous solution containing 12 grams of binary mixtures of emulsifiers - Prox the Nol 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added to the electrolyte to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFOB/PPTP in proportion to 1.63; PFOB - 372 g/l; PPTP - 228 g/l; emulsifiers 120 g/l; NaCl - 6.0 g/l; NaH2PO40.2 g/l

Received performoperation-proksanola composition can be used for external, internal, internal use, as an ointment or cream in the medical and cosmetic purposes.

Example 5. Obtaining a composition of 60% performoperation-proksanola emulsion PFOB/PTBA.

Perfluorocarbon mixture PFOB/PTBA (in proportion 1,63) in an amount of 30 ml containing sample (liquid) 37,2 g PFOB and 22.8 g PTBA was mixed with 70 ml of an aqueous solution containing 12 grams of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added to the electrolyte to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFOB/PFTB in proportion 163; PFOB - 372 g/l; PTBA - 228 g/l; emulsifiers 120 g/l; NaCl - 6.0 g/l; NaH2PO40.2 g/l

Received performoperation-proksanola composition can be used for external, internal, internal use, as an ointment or cream in the medical and cosmetic purposes.

Example 6. Receive 20% performoperation-proksanola emulsion PFOB/PFMRP.

Perfluorocarbon mixture PFOB/PFMRP (in proportion 1,95) in an amount of 10 ml containing sample (liquid) 13,24 g PFOB and 6.76 g PFMRP was mixed with 90 ml of an aqueous solution containing 4 grams of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added to the electrolyte to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFOB/PFMSP in proportion 1,95; PFOB - 132,4 g/l; PFMSP - of 67.6 g/l; emulsifiers - 40; NaCl - 6,0%; NaH2PO4to 0.2%.

Received performoperation-proksanola composition can be used as a radiopaque contrast agent for intravenous and intra-arterial injection, oral, intraoral, internal use.

Example 7. Obtaining a composition of 60% performoperation-proksanola is mulshi PPTP/PTBA.

Perfluorocarbon mixture PPTP/PTBA (in proportion 1,63) in an amount of 30 ml containing sample (liquid) 37,2 g PPTP and 22.8 g PTBA was mixed with 70 ml of an aqueous solution containing 12 grams of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added to the electrolyte to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PPTP/PFTB in proportion to 1.63; PPTP - 372 g/l; PTBA - 228 g/l; emulsifiers 120 g/l; NaCl - 6.0 g/l; NaH2PO40.2 g/l

Received performoperation-proksanola composition can be used for external, internal, internal use, as an ointment or cream in the medical and cosmetic purposes.

Example 8. The receiving part 19,58% performoperation-proksanola emulsion PFD/PFMRP.

Perfluorocarbon mixture PFD/PFMRP (in proportion 1,99) in an amount of 10 ml containing sample (liquid) 13,03 g PFD and 6,55 g PFMRP was mixed with 90 ml of an aqueous solution containing 4 grams of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After this is about in the received perfluorocarbon emulsion was added to the electrolyte to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFD/PFMSP in proportion 1,99; PFD - 130,3 g/l; PFMRP is 65.5 g/l; emulsifiers - 40; NaCl - 6.0 g/l; KCl - 0.39 g/l; MgCl2to 0.19 g/l; NaHCO3- 0.65 g/l; NaH2PO40.2 g/l; glucose - 2.0 g/L.

Received performoperation-proksanola composition can be used as a blood and perfusion means when intracavitary, internal and external use.

Example 9. The receiving part 100% performoperation-proksanola emulsion PFD/PFMRP.

Perfluorocarbon mixture PFD/PFMRP (in proportion 1,63) in an amount of 50 ml, containing sample (liquid) PFD - 62 g; PFMSP - 38, the Specific density of perfluorocarbons ~2, so 1 gram of PFOS has a volume of 0.5 ml (PFOS 100% = 50%). Then this mixture was mixed with 50 ml of an aqueous solution containing 20 grams of binary mixtures of emulsifiers - proxanol is chosen 268 and 168. The mixture of perfluorocarbons and emulsifiers was passed through the extrusion device of the high-pressure homogenizer. After that, the obtained perfluorocarbon emulsion was added to the electrolyte to the desired concentration.

The final formulation (dosage form) performoperation-proksanola emulsion had the following composition: PFD - 620 g/l; PFMSP 380 g/l; emulsifiers - 200 g/l; NaCl 6 g/l; NaH2PO40.2 g/l

Polucen the th performoperation-proksanola composition can be used for exterior, intracavitary, internal use, as an ointment or cream in the medical and cosmetic purposes.

1. The composition of perfluorocarbon blood emulsion for biomedical purposes, including: perfluorocarbons, emulsifying agents and an electrolyte solution, characterized in that it contains a binary mixture in a ratio of from of 1.55 to 1.99 of two perfluorocarbons:
- performanceline/performapply;
- performanceline/performability;
- performanceline/performancecriteria;
- performancebased/performapply;
- performancebased/performability;
- performancebased/performancecriteria;
- performapply/performancecriteria;
- performapply/performability;
- performancecriteria/performability;
- perfluorocarbons a concentration of 5 g/l to 1000 g/l, with an average particle size of PFOS from 25 to 250 nm;
binary mixture in a ratio of from of 1.55 to 1.99 of two emulsifiers - nonionic block copolymers of ethylene oxide and propylene oxide - proksanola:
- proxanol is chosen - 268/proxanol is chosen - 168;
- proxanol is chosen - 268 a concentration of 1 g/l to 200 g/l with a molecular weight of from 7 to 14 tisda;
- proxanol is chosen - 168 a concentration of 1 g/l to 200 g/l with a molecular mass of from 5 to 7 tisda;
electrolyte solution: NaH 2PO4- 0,18-0,25 g/l; NaCl - 5,5-6,5 g/l; and/or KCl - 0,37-0,41 g/l; and/or MgCl2- to 0.17-0.21 g/l; and/or NaHCO3- 0,35-0,70 g/l; and/or glucose - 1.5-2.5 g/L.

2. The tool is based on the composition of perfluorocarbon blood emulsion according to claim 1 intended for use as a synthetic perfluorocarbon blood substitute and means for the treatment of various diseases, characterized in that the composition can be used as a gas substitute blood for intravenous, intra-arterial, oral, endocavitary applications, as well as perfusion, contrast and cosmetic products, before eating can divorce any compatible with the emulsion solution or composition, including antiviral, antibacterial, antifungal composition can also be used as an external tool for cosmetic and medicinal ointments or creams for the treatment of wounds, ulcers, other external diseases.



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery, anesthesiology and intensive therapy, oncology, and can be applied in operations on account of non-organ retroperitoneal tumours. For this purpose prognostic criteria are determined on the basis of clinical and anamnestic parameters: Long stands for longitudinal dimension of tumour, in cm; Transv stands for transverse dimension of tumour, in cm; Rad stands for radical character of operation: 1 point means presence of radical intervention; 0 points means absence, palliative surgery, exploratory laparotomy; AddRes means carrying out additional resection of organs: 1 point means presence of organ resection; 0 points means operation only on tumour ablation; PorS stands for surgery on main vessels: 1 point stands for vascular plasty of arteries, resection of fragments of inferior vena cava, aorta; DifG stands for diffusion growth of tumour without capsulation: 1 point means presence; 0 points means absence. After that, coefficient of regression Z is calculated: Z=-0.581+0.038×Long+0.02×Transv+0.073×Rad+0.166×AddRes+0.133×PorS+0.102×DifG and substituted into formula: P1=11+e(1,24,18×Z) where e is base of natural logarithm with value e=2.72. If P1 constitutes from 0.87 to 0.26, massive intraoperative blood loss, requiring increased dose of colloids, but not more than 40 ml/kg/day in carrying out infusion therapy, is predicted.

EFFECT: method makes it possible to select optimal tactics of compensation of intravascular volume of colloids in operations in said category of patients due to more accurate calculation of blood loss volume.

1 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to intensive therapy and narcology, and can be used in treatment of patients with frostbites, who are in the state of narcotic intoxication of different severity. For this purpose determined are: area of affection, degree of frostbite, degree of narcotic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(Cfs×S)+(Cn×MVDIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frostbite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV severity degree frostbite; S is area of affected surface, in cm2; Cn is coefficient of narcotic intoxication severity: 1.0 - in case of changed reactivity to narcotic substance; 1.5 - in case of psychic dependence (obsessive attraction); 2.0 - in case of physical dependence (compulsive attraction); 2.5 - in case of abstinence syndrome; MVDIT is minimal volume of disinfection infusion therapy in case of application of dezomorphin, equal to 1250 ml of infusion solutions per day; PN stands for physiological needs of organism during a day; PL stands for pathological loss during a day, constituting 500 ml in case of I and II degree of frostbites and 1000 ml in case of III and IV degree of frostbites.

EFFECT: method ensures adequate and differentiated performance of infusion therapy in said category of patients taking into account degree of narcotic intoxication, which contributes to prevention of "mutual aggravation", minimisation of disorders of hemostasis, microcirculation, as well as prevention of encephalopathy of complex genesis, including carrying out necrotomy and fasciotomy.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to surgery and intensive therapy, and can be used in treatment of patients with frostbites. For this purpose degree of frost bite severity, area of affection, physiological needs of organism and pathological loss during a day are determined. After that, volume of infusion therapy is calculated by formula: V-C×S+PN+PL, where: V is volume of infusion therapy, in ml; C is coefficient of frost bite severity: 1.0 in case of I and II degree frostbites; 2.0 in case of III-IV degree frostbites; S is the area of affected surface, in cm2; PN stands for physiological needs of organism during a day, in ml; PL stands for pathological loss during a day, in ml.

EFFECT: method ensures elimination of hemostasis and microcirculation disorders in pre-reactive period, as well as in early and late reactive periods due to carrying out adequate infusion therapy with optimal volume of solutions.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to narcology, and can be used in treatment of patients with frost bites, who are in the state of alcoholic intoxication of different severity. For this purpose determined are: degree of frostbite, area of affection, degree of alcoholic intoxication, physiological needs of organism and pathological loss during a day. After that, volume of infusion therapy is calculated by formula: V=(CfsxS)+(CfxSVIT)+PN+PL, where: V is volume of infusion therapy, in ml; Cfs is coefficient of frost bite severity: 1.0 in case of I and II degree frost bites; 2.0 in case of III-IV severity degree frost bite; S is area of affected surface, in cm2; Ca is coefficient of alcoholic intoxication severity: 0.5 in case of mild degree, 0.75 in case of medium severity; 1.0 in case of severe degree; 1.5 - in case of alcoholic coma; SVIT is standardised volume of infusion therapy, in case of alcoholic intoxication equal 2500 ml per day: PN stands for physiological needs of organism for a day, in ml; PL stands for pathological loss within a day, in case of I and II degree frost bites constituting 500 ml; in case of III and IV degree frost bites constituting 1000 ml.

EFFECT: method ensures adequate and differentiated carrying out infusion therapy in said category of patients, taking into account degree of alcoholic intoxication, which contributes to prevention of "mutual aggravation" syndrome, minimisation of hemostasis and microcirculation, as well as prevention of encephalopathy of complex genesis, alcoholic psychosis, including cases after carrying out necrotomy and fasciotomy.

3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to resuscitation and intensive therapy and can be used in treatment of hemorrhagic shock of I, II and II degree of severity. Method of hemorrhagic shock treatment. For this purpose, assessment of degree of hemorrhagic shock severity is carried out, and in case of hemorrhagic shock of 1 degree of severity in the programme of infusion therapy included are: crystalloid solution of isotopic sterofundin in dose 3000 ml per day and 4% colloidal solution of modified gelatin in volume 1000 ml per day, in case of hemorrhagic shock of II degree of severity - 1200 and 2500 ml respectively, in case of hemorrhagic shock of III degree of severity - 1200 and 3500 ml respectively.

EFFECT: method makes it possible to improve results of treating patients with hemorrhagic shock at pre-hospital and hospital stages due to reduction of risk of electrolyte and acid-alkaline disorders.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely resuscitation and may be used for prevention of severe complications in surgical management of massive and submassive blood loss with continuous haemorrhages. That is ensured by the intraoperative intravenous drop-by-drop introduction of Perftoran 2-4 ml/kg following mechanical arrest of the continuous haemorrhages. With underlying restorable blood volume, higher body oxygenation with eliminated nitrogen oxide inhalation. Rheamberyn is introduced in an average therapeutic dose at the end of the operation and on the first three postoperative days.

EFFECT: invention provides higher effectiveness of infusion-transfusion management, improved clinical course of the operative and postoperative period, reduced percentage of complications and mortality.

2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is prescribed is taking a beverage made of soluble granulated magnolia-vine extract. The beverage 250 ml is taken before a dip for 20 days three times a day.

EFFECT: use of the declared method enables unfavourable changes of water and electrolyte metabolism in divers.

1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine. What is prescribed is a beverage made of soluble granulated magnolia-vine extract. The beverage 250 ml is taken before a dip (compression in a vacuum chamber) for 20 days three times a day.

EFFECT: method is high-effective for prevention of compressed-air disease in divers.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine and pharmacology and represents the use of water-soluble hybrid macromolecular compounds: O-(3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionyl)-(1→6)-α-D-glucan, polyethylene glycol bis-3-(3,5-di-tert-butyl-4-hydroxyphenyl)-propionate as agents improving survival rate in wound shock.

EFFECT: invention provides the extended range of products applied in therapy for wound shock.

4 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to combuistology, resuscitation and intensive care, narcology and can be used in patients in state of drug intoxication with use of desomorphine. For this purpose determined are patient's body weight, degree of drug intoxication expression and physiological needs of organism during a day. After that volume of deintoxication-infusion therapy is calculated by formula: V= Cdix(CsxBW)+ PN, where V is volume of infusion therapy, in ml; Cdi - coefficient of drug intoxication expression: 1.0 in case of changed reactivity to drug substance; 1.5 - in case of presence of psychic dependence (obsessive attraction); 2.0 - in case of presence of physical dependence (compulsive attraction); 2.5 - in case of abstinence syndrome; Cs is coefficient of somatic aggravation with use of desomorphine, equal 0.2; BW is patient's body weight in grams; PN is physical needs of organism during a day, in ml.

EFFECT: method makes it possible to ensure adequate infusion therapy in patients with different degree of expression of drug intoxication with desomorphine.

1 ex

FIELD: medicine.

SUBSTANCE: agent contains 0.2% Pyriton, an emulsifier, an emollient - isopropyl myristate, and a solvent. The emulsifier is presented by glycerol cocoate PEG-7; the emollient is presented by triglycerides of caprylic and capric acids; the solvent is water. Besides, the agent additionally contains glycerol, cyclomethicone, urea, allantoin and a flavouring agent. All the ingredients of the agent are taken in certain mass ratio.

EFFECT: invention enables eliminating side effects, recovering physiological properties of skin and providing high patient's satisfaction upon completion of the treatment.

1 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention discloses a cream for external treatment of Graham-Little-Piccardi-Lasseur syndrome, which contains lanolin, peach oil and distilled water, and is characterised by that it further contains chloroquine, wherein components of the cream are in a defined ratio given in g%.

EFFECT: inhibiting progression of scarring without marked side effects.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of cosmetology, namely to a cosmetic composition for peroral introduction, which contains a combination of lycopene, vitamin C, vitamin E and at least one polyphenol compound, obtained from pine bark, in which the ratio of weight content of polyphenol compound to the sum of weight contents of lycopene, vitamin C and vitamin E constitutes from 0.3 to 0.7, as s single active ingredient.

EFFECT: invention is intended for prevention and/or treatment of wrinkles in the area of eyes and mouth angles, small wrinkles, eye bags and dark circles under eyes.

22 cl, 2 ex, 11 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: there are presented: using nalbuphine salt in the form of a hydrophilic emulsion suppository for treating moderate to severe pain syndrome, a pharmaceutical composition for the same application in the form of suppositories comprising nalbuphine hydrochloride as an active substance and a hydrophilic emulsion base in the following ratio, g/100 g of the composition: nalbuphine hydrochloride 0.0125-5.00, hydrophilic emulsion base up to 100 g, and a method for preparing the same.

EFFECT: effective and prolonged analgesic action with no laxative action has been shown.

7 cl, 3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology and immunology. What is presented is a method for preparing a vaccine with using reverse latex. The first stage involves preparing an adjuvant composition by dispersion of reverse latex or polymer powder prepared by reverse latex spraying, in a physiologically acceptable solution. The second stage involves mixing the prepared adjuvant composition with an antigen-containing medium for preparing the vaccine composition.

EFFECT: reverse latex adjuvant is characterised by higher safety and possesses the high adjuvant effect both at the level of the humoral response, and at the level of the cell response.

8 cl, 2 dwg, 3 ex

Topical composition // 2497516

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a topical pharmaceutical composition in the form of an opaque emulsion gel. The composition contains 1.2-4 wt % of diclofenac diethylammonium salt, saturated or unsaturated C10-C18fatty alcohol, at least 40 wt % of water, C2-C4alkanol, glycol solvent, gelling agent, liquid lipid forming an oil phase of the emulsion gel, non-ionic surfactant and agent with the primary properties to reduce pH of the prepared composition to 6-9.

EFFECT: compositions under the invention are characterised by high skin permeability, extremely low systemic absorption, absence of human skin irritation after application, high chemical and physical stability, complete solubility of the active component and considerable relief of pain intensity.

8 cl, 4 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to chemical-pharmaceutical industry and represents a pharmaceutical composition for treating or preventing AIDS in an orally acceptable presentation containing: 1 to 99 wt % of at least one zeolite, montmorillonite or a mixture thereof as the ingredient F; 1 to 99 wt % of at least raw or dried blue-green algae as the ingredient G; 0 to 50 wt % of conventional pharmaceutical excipients and additives as the ingredient H; the total amount of the ingredients F, G and optionally H makes 100 wt %, with the weight ratio of the ingredients F and G at a dry basis falls within the range of 0.2:1 to 5:1.

EFFECT: invention provides creating a composition for treating or preventing AIDS containing a combination of zeolites and algae drugs.

11 cl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutical formulations and methods for preparing them of lipids for ophthalmological application containing a phospholipid ingredient containing natural zwitterion phospholipids, and an oil ingredient containing natural oil-in-water emulsions. The oil ingredient and phospholipid ingredient are preferentially related as 3:1; the phospholipid ingredient is found in the amount of 0.1%-5%, and the oil ingredient is found in the amount of 0.3%-15%.

EFFECT: group of inventions provides ocular drug delivery applicable for treating dry eye syndrome; it has an ability to recover the lipid lachrymal film layer, inhibits the inflammatory element observed.

37 cl, 19 tbl, 4 ex, 7 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a nanoemulsion as a carrier of a biologically active substance representing a DSIP or a herbal extract. The nanoemulsion contains water, a surfactant representing an ethylene oxide/ propylene oxide block copolymer, and a biopolymer in the form of mixed polysaccharide (PS) and polyaminosaccharide (PAS). The polysaccharide is 2-diethylaminoethyl-dextran or 3-dimethylaminopropyl-dextran. The polyaminosaccharide is chitosan or a chitosan derivative prepared by exhaustive alkylation of primary amino groups by glycidyl trimethylammonium chloride. The mass content of each of the polymers (ethylene oxide/ propylene oxide block copolymer, PS and PAS) in the mixture of polymers and nanoemulsion is found within the range of 0.1 to 0.7, while the ethylene oxide/ propylene oxide block copolymer concentration makes 0.4-4.0 g/l.

EFFECT: invention provides preparing the biologically compatible and storage-stable nanoemulsion.

2 cl, 7 ex

Nanoemulsion // 2491917

FIELD: medicine.

SUBSTANCE: group of inventions refers to a nanoemulsion for active agent delivery, a method for preparing it, compositions containing it, and to using a nanoemulsion for preparing pharmaceutical compositions for local application and cosmetic compositions for skin application. The declared nanoemulstion contains a water ingredient and a carrier which contains a lipophilic ingredient in the amount of 0.1-15 wt %, a surfactant and isopropyl and/or 1-propyl alcohol. The average emulsified particle diameter makes less than 100 nm. The method for preparing the nanoemulsion involves mixing the water ingredient and carrier containing the lipophilic ingredient, surfactant and isopropyl and/or 1-propyl alcohol, for preparing the nanoemulsion at temperature 50-60°C. The invention also refers to the composition for photodynamic therapy containing the above nanoemulsion and the active agent representing 5-aminolevulinic acid, a derivative, a precursor and/or a metabolite thereof. The above composition is applied to prepare the drug substance for photodynamic therapy and to treat senile keratosis. What is also declared is a diagnostic composition for detecting the dividing cells which contains the nanoemulsion and 5-aminolevulinic acid. The invention also refers to a kit for photodynamic therapy which comprises the composition for photodynamic therapy and one ingredient specified in a photoresist coating, an agent for attaching the above coating or an agent for applying the composition.

EFFECT: invention provides better stability and intensified cell and tissue penetration of the nanoemulsion.

25 cl, 6 dwg, 9 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to method of obtaining microcapsules of medication of cephalosporin group in poludanum. In accordance with claimed method cephalosporin powder and surface-active substance are added to aqueous solution of poludanum, mixture is mixed until components dissolve completely, after formation of transparent solution carbinol and after it isopropyl alcohol are additionally poured in. Obtained suspension of microcapsules is filtered, washed with acetone and dried in dessicator.

EFFECT: invention makes it possible to simplify and accelerate process of obtaining microcapsules of water-soluble medications of cephalosporin groups in poludanum, as well as to increase their output by weight.

4 ex

Up!